HTLV-I/II seropositivity and death from AIDS among HIV-1 seropositive intravenous drug users

John Page, S. Lai, D. D. Chitwood, N. G. Klimas, P. C. Smith, M. A. Fletcher

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

In a prospective study of street-recruited intravenous drug users (IVDUs) in Miami, Florida, USA, 107 (46·5%) of 230 IVDUs were infected with HIV-1. Of these HIV-1 seropositive individuals, 23 were also infected with human T-lymphotropic virus type I or II (HTLV-I/II). To test the hypothesis that HTLV-I/II infection has an effect on the survival of HIV-1 seropositive IVDUs, various baseline clinical and laboratory HIV-1 related indices in HTLV-I/II positive and negative groups were compared. Life table analysis and Cox's proportional hazards model were used to estimate the potential effect of HTLV-I/II infection on the survival patterns of people infected with HIV-1. IVDUs infected with both viruses were three times more likely to die from AIDS during follow-up than were those infected with HIV-1 only. This finding suggests that HTLV-I/II seropositivity may adversely affect the clinical outcome of HIV-1 seropositive patients.

Original languageEnglish
Pages (from-to)1439-1441
Number of pages3
JournalThe Lancet
Volume335
Issue number8703
DOIs
StatePublished - Jun 16 1990

Fingerprint

Human T-lymphotropic virus 2
HIV Seropositivity
Drug Users
HIV-1
Life Tables
Survival
Infection
Proportional Hazards Models
Acquired Immunodeficiency Syndrome
Prospective Studies
Viruses

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Page, J., Lai, S., Chitwood, D. D., Klimas, N. G., Smith, P. C., & Fletcher, M. A. (1990). HTLV-I/II seropositivity and death from AIDS among HIV-1 seropositive intravenous drug users. The Lancet, 335(8703), 1439-1441. https://doi.org/10.1016/0140-6736(90)91456-K

HTLV-I/II seropositivity and death from AIDS among HIV-1 seropositive intravenous drug users. / Page, John; Lai, S.; Chitwood, D. D.; Klimas, N. G.; Smith, P. C.; Fletcher, M. A.

In: The Lancet, Vol. 335, No. 8703, 16.06.1990, p. 1439-1441.

Research output: Contribution to journalArticle

Page, J, Lai, S, Chitwood, DD, Klimas, NG, Smith, PC & Fletcher, MA 1990, 'HTLV-I/II seropositivity and death from AIDS among HIV-1 seropositive intravenous drug users', The Lancet, vol. 335, no. 8703, pp. 1439-1441. https://doi.org/10.1016/0140-6736(90)91456-K
Page, John ; Lai, S. ; Chitwood, D. D. ; Klimas, N. G. ; Smith, P. C. ; Fletcher, M. A. / HTLV-I/II seropositivity and death from AIDS among HIV-1 seropositive intravenous drug users. In: The Lancet. 1990 ; Vol. 335, No. 8703. pp. 1439-1441.
@article{e7754b1f8ea74f74b6e859c676407e8c,
title = "HTLV-I/II seropositivity and death from AIDS among HIV-1 seropositive intravenous drug users",
abstract = "In a prospective study of street-recruited intravenous drug users (IVDUs) in Miami, Florida, USA, 107 (46·5{\%}) of 230 IVDUs were infected with HIV-1. Of these HIV-1 seropositive individuals, 23 were also infected with human T-lymphotropic virus type I or II (HTLV-I/II). To test the hypothesis that HTLV-I/II infection has an effect on the survival of HIV-1 seropositive IVDUs, various baseline clinical and laboratory HIV-1 related indices in HTLV-I/II positive and negative groups were compared. Life table analysis and Cox's proportional hazards model were used to estimate the potential effect of HTLV-I/II infection on the survival patterns of people infected with HIV-1. IVDUs infected with both viruses were three times more likely to die from AIDS during follow-up than were those infected with HIV-1 only. This finding suggests that HTLV-I/II seropositivity may adversely affect the clinical outcome of HIV-1 seropositive patients.",
author = "John Page and S. Lai and Chitwood, {D. D.} and Klimas, {N. G.} and Smith, {P. C.} and Fletcher, {M. A.}",
year = "1990",
month = "6",
day = "16",
doi = "10.1016/0140-6736(90)91456-K",
language = "English",
volume = "335",
pages = "1439--1441",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "8703",

}

TY - JOUR

T1 - HTLV-I/II seropositivity and death from AIDS among HIV-1 seropositive intravenous drug users

AU - Page, John

AU - Lai, S.

AU - Chitwood, D. D.

AU - Klimas, N. G.

AU - Smith, P. C.

AU - Fletcher, M. A.

PY - 1990/6/16

Y1 - 1990/6/16

N2 - In a prospective study of street-recruited intravenous drug users (IVDUs) in Miami, Florida, USA, 107 (46·5%) of 230 IVDUs were infected with HIV-1. Of these HIV-1 seropositive individuals, 23 were also infected with human T-lymphotropic virus type I or II (HTLV-I/II). To test the hypothesis that HTLV-I/II infection has an effect on the survival of HIV-1 seropositive IVDUs, various baseline clinical and laboratory HIV-1 related indices in HTLV-I/II positive and negative groups were compared. Life table analysis and Cox's proportional hazards model were used to estimate the potential effect of HTLV-I/II infection on the survival patterns of people infected with HIV-1. IVDUs infected with both viruses were three times more likely to die from AIDS during follow-up than were those infected with HIV-1 only. This finding suggests that HTLV-I/II seropositivity may adversely affect the clinical outcome of HIV-1 seropositive patients.

AB - In a prospective study of street-recruited intravenous drug users (IVDUs) in Miami, Florida, USA, 107 (46·5%) of 230 IVDUs were infected with HIV-1. Of these HIV-1 seropositive individuals, 23 were also infected with human T-lymphotropic virus type I or II (HTLV-I/II). To test the hypothesis that HTLV-I/II infection has an effect on the survival of HIV-1 seropositive IVDUs, various baseline clinical and laboratory HIV-1 related indices in HTLV-I/II positive and negative groups were compared. Life table analysis and Cox's proportional hazards model were used to estimate the potential effect of HTLV-I/II infection on the survival patterns of people infected with HIV-1. IVDUs infected with both viruses were three times more likely to die from AIDS during follow-up than were those infected with HIV-1 only. This finding suggests that HTLV-I/II seropositivity may adversely affect the clinical outcome of HIV-1 seropositive patients.

UR - http://www.scopus.com/inward/record.url?scp=0025338703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025338703&partnerID=8YFLogxK

U2 - 10.1016/0140-6736(90)91456-K

DO - 10.1016/0140-6736(90)91456-K

M3 - Article

VL - 335

SP - 1439

EP - 1441

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8703

ER -